Early access
Sign in
Enrolling by invitationNo phase

Lower-cost hCG-based egg stimulation compared with standard medicines in IVF for infertility

Compares an hCG-based ovarian stimulation with standard medicines in women having IVF.

Key facts

Who runs it
LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro
Where
Uganda and Ukraine3 sites in 2 countriesChoose a country to see its sites
Trial code
Registry title
Purpose to Evaluate the Effectiveness of the Superovulation Stimulation Protocol Using Human Chorionic Gonadotropin (hCG) by Demonstrating Its Equivalence to Standard Controlled Ovarian Stimulation Protocols in Terms of Oocytes Retrieved, Blastulation While Maintaining an Economic Advantage
Status
Enrolling by invitation
People taking part
360 people, planned
Started
17 Aug 2026
Expected to end
1 May 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Human Chorionic Gonadotropin (hCG)
  • GnRH antagonist
  • Dual trigger (human chorionic gonadotropin plus GnRH-agonist)
  • Gonadotropins (FSH or FSH/LH)
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 to 40 who need ovary stimulation as part of IVF or other assisted reproduction. It compares a lower-cost hCG protocol with the standard medicine protocol.

Age
18 to 40 years
Sex
Women only
Disease stage
Infertility with a medical reason for ovary stimulation in an IVF or assisted reproduction program. Any level of egg reserve can join.
Biomarker or test result
Body Mass Index (BMI) up to 35 kg/m².

Main reasons for not taking part

  • Endometriomas (cysts of endometriosis) in the ovaries
  • Past severe Ovarian Hyperstimulation Syndrome (OHSS), an overreaction of the ovaries
  • Severe hormone (endocrine) disorders
  • Cancer now or in the past
  • Severe male partner infertility (cryptozoospermia), or any medical reason that rules out hormone stimulation

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Women of reproductive age between 18 and 40 years
  • Clinical indications for the induction of superovulation (undergoing ART/IVF programs)
  • Patients with all variants of ovarian reserve
  • Body Mass Index (BMI) up to 35 kg/m²
  • Provision of informed consent to participate in the research study

Who cannot take part

  • History of severe Ovarian Hyperstimulation Syndrome (OHSS) in previous cycles
  • Presence of severe endocrine disorders
  • History or presence of oncological diseases
  • Presence of ovarian endometriomas
  • Any medical contraindications to hormonal stimulation
  • Severe male factor infertility (specifically cryptozoospermia)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates a more affordable medication protocol for ovarian stimulation during in vitro fertilization (IVF). Standard IVF protocols use medications called gonadotropins to stimulate the ovaries to produce multiple eggs, but these medications can be very expensive and create a barrier to treatment. This clinical trial tests whether substituting a significant portion of these standard medications with human chorionic gonadotropin (hCG) is just as effective. Researchers will compare the number and quality of eggs and embryos produced by women using the experimental hCG protocol versus those using the standard gonadotropin protocol. The main goal is to determine if the hCG method can provide similar clinical outcomes and safety profiles while significantly reducing the overall financial cost of IVF treatment.

The 2 groups in the trial

  • hCG ProtocolTreatment being tested

    atients in this group undergo ovarian stimulation where human chorionic gonadotropin (hCG) replaces standard gonadotropins (or a significant portion of them) once the main cohort of follicles reaches 11-12 mm in size. This arm utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation.

    Treatment: Human Chorionic Gonadotropin (hCG), GnRH antagonist, Dual trigger (human chorionic gonadotropin plus GnRH-agonist), and Gonadotropins (FSH or FSH/LH)

  • Standard ProtocolExisting treatment, for comparison

    Patients in this group undergo standard controlled ovarian stimulation using continuous administration of gonadotropins. This arm also utilizes a fixed gonadotropin-releasing hormone (GnRH) antagonist protocol starting on day 6 of stimulation and a dual trigger for final maturation

    Treatment: GnRH antagonist, Dual trigger (human chorionic gonadotropin plus GnRH-agonist), and Gonadotropins (FSH or FSH/LH)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective Randomized Single-Blind Study of the Effectiveness of the Superovulation Stimulation Protocol Using hCG Compared to Standard Protocols With Different Gonadotropin Doses in In Vitro Fertilization Programs
Plain-language title
Lower-cost hCG-based egg stimulation compared with standard medicines in IVF for infertilityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT07771283, who can take part
Record updated
27 August 2026